Study of AZD0754 in Participants with Metastatic Prostate Cancer - APOLLO

Study identifier:D9660C00001

ClinicalTrials.gov identifier:NCT06267729

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Phase I/II Open Label Study to Evaluate the Safety, Cellular Kinetics, and Efficacy of AZD0754, a Chimeric Antigen Receptor (CAR) T-cell Therapy Directed Against STEAP2, in Adult Participants with Metastatic Prostate Cancer: APOLLO

Medical condition

Metastatic Prostate Cancer

Phase

Phase 1/2

Healthy volunteers

No

Study drug

-

Sex

Male

Estimated Enrollment

60

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 12 Mar 2024
Estimated Primary Completion Date: 24 May 2027
Estimated Study Completion Date: 24 May 2027

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 May 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria